Bronte Lambourne

Dexus has stood down executives, sacked its advisers and launched a review of its $7 billion infrastructure division, following last week's judgment upholding the validity of a default notice by Melbourne Airport's operator.

Heads may roll after a court on Friday rejected the evidence of key Dexus employees at trial over a breach of APAC's shareholder deed, in a ruling that revealed some insiders suspected the "embarassing blunder" would come back to bite.

A long-running class action over the construction of the Sydney light rail that was revived by the High Court is heading to mediation, with a judge noting the challenges that lie ahead in determining all the claims of group members if the parties don't settle.

A senior in-house lawyer at Dexus has rejected suggestions she was “careless” in her role in the sale of shares in Melbourne Airport operator APAC, saying she relied on a subordinate lawyer and others within the business. 

Lawyers assured two Dexus executives that it was OK to share the confidential information of Melbourne Airport operator APAC with proposed purchasers of the real estate asset manager's stake in the company, a court has heard.

Uber drivers seeking to challenge their classification as independent contractors have argued the rideshare giant had “highly prescriptive” rules on how to behave towards customers, including 'no touching' and 'no sex' rules. 

The High Court has revived a class action by small business owners over the interference caused by the construction of the Sydney light rail network.

The High Court has revived a class action by small business owners over the interference caused by the construction of the Sydney light rail network.

Special purpose liquidators have been appointed to failed clothing retailer Mosaic Brands, after a judge found a reasonable apprehension of bias arising from liquidator Vaughan Strawbridge's former link to Deloitte.

The Takeovers Panel has found Cosette cannot close a Mayne Pharma drug manufacturing plant in Adelaide, another win for Mayne in its push to block the US drug maker from walking away from their $672 million merger.